We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) (STRONG SCD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03285178
Recruitment Status : Completed
First Posted : September 15, 2017
Last Update Posted : July 22, 2021
Information provided by (Responsible Party):
Cyclerion Therapeutics

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 22, 2020
Actual Study Completion Date : July 22, 2020
Certification/Extension First Submitted : July 18, 2021